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Daunton et al report a study exploring the practice of dermatologists prescribing  
isotretinoin in 4 different clinical scenarios with different degrees of theoretical risk of 
deterioration in emotional health / suicide.1 The results show a degree of therapeutic  
timidity in some respondents which is to be expected and based on a number of 
variables including cognitive biases.2  In May 2018 we recently surveyed members of 
the Scottish Dermatology Society (SDS) using survey-monkey® to assess their 
perception and experience of mood disturbance in patients taking isotretinoin for 
acne. We received 48 respondents (32 of which were Consultant Dermatologists 
(67% of total respondents ). The SDS membership is fluid but at the time of the 
survey there were 314 members of which 118 were Consultant Dermatologists. Not 
all members are clinicians. A conservative estimated response rate therefore was 
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48/314 = 15%. 38% of respondents did not believe that isotretinoin can cause 
depression; however, 71% admit to worrying about patients’ mental health and 87% 
had stopped isotretinoin due to concern about mental health. Self-rated confidence 
in dermatologists’ ability to perform a psychiatric assessment varied with only 6% 
feeling extremely or very confident, but only 25% used a questionnaire to aid mental 
wellbeing assessment. 29% ask about suicidal thoughts in every consultation and 
71% ask only if signs of low mood were present. Reassuringly, only 2 respondents 
reported a completed suicide of a patient while taking isotretinoin in their career to 
date (out of an approximate cumulative total of 695 years of clinical practice of 
respondents). There are approximately 700 cases of completed suicide in Scotland 
per year of which 250 occur in young adults.3 We estimate the expected number of 
completed suicides for the number and age of patients seen to be 3.6 based on 
known population data for Scotland.3  Therefore, our findings would be in keeping 
with the reports from previous studies that have not found an increased prevalence 
of completed suicide associated with isotretinoin use although no firm conclusions 
can be made due to the limitations of our study. 
We agree that using a validated screening questionnaire eg the HADS and / or PHQ-
9 helps in assessment and monitoring of distress, depressive symptoms, anxiety and 
suicidal ideation. We also agree that referral to psychiatry is rarely indicated. 
Some individuals are constitutionally predisposed to depression and suicidal 
ideation. Acne can be an independent risk factor for depression and this risk may 
increase with lack of effective treatment for acne eg withholding or delaying 
isotretinoin therapy. Isotretinoin is usually a highly effective treatment for acne and 
so can improve wellbeing and reduce suicide risk.4 However, in a minority of 
patients, isotretionoin appears to unmask depressive symptoms and suicidal 
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ideation. Unfortunately, no one can accurately predict suicide and no specific tests 
are capable of identifying a suicidal person. However, in the context of an individual 
with acne having isotretinoin we suggest that individuals may be more at risk if there 
is a disappointing response to treatment, recurrent acne requiring multiple courses of 
isotretinoin, first time suicidal thoughts whilst taking isotretinoin and a lack of 
improvement in wellbeing despite successful clearing of acne.5 Other skin-
associated risk factors include a disproportionate appearance concern / acne 
dysmorphia6, and general risk factors eg. feelings of hopelessness, social isolation 
and co-existing physical illness. Bipolar disorder often deteriorates with isotretinoin in 
our experience and others and we suggest this is a caution.7 We agree that liaising 
with the GP and / or psychiatry is indicated in individual cases and more frequent 
follow-up. Clear communication is important and robust mechanisms should be in 
place should a crisis arise eg supplying emergency contact phone numbers. 
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